Investigating the effect of subcutaneous erythropoietin on blood transfusions requirement in trauma patients admitted to the surgical intensive care unit (SICU)

Investigating the effect of subcutaneous erythropoietin on blood transfusions requirement in trauma patients admitted to the surgical intensive care unit (SICU): A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250621066213N1

Enrollment

140

Registered

2025-07-01

Start date

2025-07-11

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Investigating the need for blood transfusion in trauma patients receiving subcutaneous erythropoietin..

Interventions

Intervention 1: Intervention group: Intervention group receiving erythropoietin and standard care .A dose of 30,000 units of recombinant human erythropoietin (rHuEPO) will be administered subcutaneous

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Adult patients 18-65 years old Patients admitted to the SICU with traumatic injuries associated with femur fractures Hemoglobin level 8 to 12 g/dL upon admission to the ICU Informed consent has been obtained from the patient or their legal representative.

Exclusion criteria

Exclusion criteria: Patients with pre-existing hematological disorders (such as polycythemia Vera) Patients with a history of erythropoietin sensitivity Pregnant or breastfeeding women Patients with chronic kidney disease who require dialysis Patients who have previously received erythropoietin or other red blood cell stimulating agents Patients with a history of high blood pressure Cancer patients Patients with a history of thrombosis or current acute thrombosis

Design outcomes

Primary

Measure	Time frame
Number of blood transfusions required during SICU stay. Timepoint: During hospitalization in the intensive care unit. Method of measurement: Number of units of blood transfused.	—

Secondary

Measure	Time frame
Hemoglobin level. Timepoint: When admitted to the ICU, weekly intervals, and discharged from the ICU. Method of measurement: grams per deciliter.;Hematocrit level. Timepoint: When admitted to the ICU, weekly intervals, and discharged from the ICU. Method of measurement: percentage.;Length of stay in the intensive care unit. Timepoint: When discharged from the ICU. Method of measurement: number of days.;Occurrence of thromboembolic complications. Timepoint: during ICU stay. Method of measurement: yes/no.	—

Measure

Time frame

Hemoglobin level. Timepoint: When admitted to the ICU, weekly intervals, and discharged from the ICU. Method of measurement: grams per deciliter.;Hematocrit level. Timepoint: When admitted to the ICU, weekly intervals, and discharged from the ICU. Method of measurement: percentage.;Length of stay in the intensive care unit. Timepoint: When discharged from the ICU. Method of measurement: number of days.;Occurrence of thromboembolic complications. Timepoint: during ICU stay. Method of measurement: yes/no.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab Alizadeh

Yasouj University of Medical Sciences

Alizadeh.md6010@gmail.com+98 74 3232 4568

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026